Nadja C. Fenn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadja C. Fenn has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Humpe
LMU Munich 3 Department of Transfusion Medicine, Cellular Therapeutics and Hemostaseology, University Hospital Munich, Germany
10 shared publications - Anja Wittner
Ludwig-Maximilians-Universität München 2 Gene Center and Department of Biochemistry Munich, Germany
10 shared publications - Fabian Schuurmans
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
10 shared publications - Gosse J. Adema
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
10 shared publications - Karl-Peter Hopfner
Gene Center, Department of Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany
10 shared publications - Maaike W.G. Looman
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 3 shows the gating strategy used for the BMDM phagocytosis assay, phagocytosis of the 9464D parental cell line, representative images showing EL4-GD2 phagocytosis using life cell imaging and quantification of maximum phagocytosis levels derived from dose-response curves.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 3 shows the gating strategy used for the BMDM phagocytosis assay, phagocytosis of the 9464D parental cell line, representative images showing EL4-GD2 phagocytosis using life cell imaging and quantification of maximum phagocytosis levels derived from dose-response curves.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary table 2 shows the complete amino acid sequences of the aGD2(-SIRPα fusion) mAbs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary table 2 shows the complete amino acid sequences of the aGD2(-SIRPα fusion) mAbs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 1 shows the schematical configuration of the aCD33-SIRPα fusion and aGD2(-SIRPα fusion) mAbs, purification of aCD33-SIRPa fusion mAbs and thermal stability of the aGD2(-SIRPα fusion) mAbs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 1 shows the schematical configuration of the aCD33-SIRPα fusion and aGD2(-SIRPα fusion) mAbs, purification of aCD33-SIRPa fusion mAbs and thermal stability of the aGD2(-SIRPα fusion) mAbs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 5 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 5 shows the expression of CD16, CD47 and SIRPα on moMacs, the gating strategy used for the moMac phagocytosis assay, dose response curves of MCF-7 and SHEP-2 phagocytosis induced by aGD2(-SIRPα fusion) and aCD33-SIRPα fusion mAbs and the expression of TNFα in moMac cultures stimulated with or without LPS in presence of the various aGD2(-SIRPα fusion) maBs, aCD33(-SIRPα fusion) mAbs, CV1 or a combination of aGD2 and CV1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 5 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 5 shows the expression of CD16, CD47 and SIRPα on moMacs, the gating strategy used for the moMac phagocytosis assay, dose response curves of MCF-7 and SHEP-2 phagocytosis induced by aGD2(-SIRPα fusion) and aCD33-SIRPα fusion mAbs and the expression of TNFα in moMac cultures stimulated with or without LPS in presence of the various aGD2(-SIRPα fusion) maBs, aCD33(-SIRPα fusion) mAbs, CV1 or a combination of aGD2 and CV1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 4 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 4 shows the effect of the SIRPα fusion mAbs on the expression of IL-10, IL-6 and TNFα in co-cultures of BMDMs with either 9464D-Luc-GFP or EL4-GD2 stimulated with LPS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 4 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 4 shows the effect of the SIRPα fusion mAbs on the expression of IL-10, IL-6 and TNFα in co-cultures of BMDMs with either 9464D-Luc-GFP or EL4-GD2 stimulated with LPS.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 2 shows binding of the aCD33(-SIRPα fusion) mAbs to human and murine (NB) cell lines and binding of SIRPα fusion mAbs to SK-N-AS and the CD47 negative cell line HEPG2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 2 shows binding of the aCD33(-SIRPα fusion) mAbs to human and murine (NB) cell lines and binding of SIRPα fusion mAbs to SK-N-AS and the CD47 negative cell line HEPG2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary table 1 shows the amino acid sequences of the individual components used for the generation of the SIRPα fusion mAbs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary table 1 shows the amino acid sequences of the individual components used for the generation of the SIRPα fusion mAbs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 6 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 6 shows NK-cell mediated killing of IMR-32 and SK-N-AS NB cell lines induced by aGD2 mAb in combination with the aCD47 mAb Magrolimab, the impact of the aGD2(-SIRPα) fusion mAbs and aCD47 on cell growth of IMR-32 and SK-N-AS in absence of NK-cells, the binding of aGD2(-SIRPα) fusion mAbs to NK-cells and the expression of GD2, CD47 and CD16 on NK-cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 6 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 6 shows NK-cell mediated killing of IMR-32 and SK-N-AS NB cell lines induced by aGD2 mAb in combination with the aCD47 mAb Magrolimab, the impact of the aGD2(-SIRPα) fusion mAbs and aCD47 on cell growth of IMR-32 and SK-N-AS in absence of NK-cells, the binding of aGD2(-SIRPα) fusion mAbs to NK-cells and the expression of GD2, CD47 and CD16 on NK-cells.
- 7 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (5) , 799-813
Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.
- 7 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (5) , 799-813
Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.